The total return over the past 12 months is +1.59% vs. +16.94% for the S&P 500. So far it's up -18.36% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +1.59% | +21.23% | (25.17%) | N/A | N/A | N/A |
| Total Return CAGR | +1.59% | +21.23% | (25.17%) | N/A | N/A | N/A |
| Revenue CAGR | (32.27%) | (17.03%) | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Taysha Gene Therapies, Inc. (TSHA)
| Year | Start price | End price | TSHA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $5.50 | $4.49 | (18.36%) | +14.51% | (32.87%) |
| 2025 | $1.73 | $5.50 | +217.92% | +17.72% | +200.20% |
| 2024 | $1.77 | $1.73 | (2.26%) | +24.89% | (27.15%) |
| 2023 | $2.26 | $1.77 | (21.68%) | +26.19% | (47.87%) |
| 2022 | $11.65 | $2.26 | (80.60%) | (18.17%) | (62.43%) |
| 2021 | $26.54 | $11.65 | (56.10%) | +28.74% | (84.84%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
